NLRP3 and ovarian endometriosis: administered the NLRP3 inhibitor MCC950 to ovarian endometriosis (OE) mice and showed that inhibition of NLRP3 inflammasome activity reduced the expression of IL-1β and Ki67 in cyst-derived stromal cells (CSCs), leading to a significant inhibition of OE lesion size (127).